Five Discovery develops non‑hallucinogenic small‑molecule neuroplastogen therapeutics that repair dysfunctional neural circuits underlying neurodegenerative diseases and brain injury.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases and traumatic brain injury are driven by dysfunctional neural circuits, maladaptive neuroplasticity, and chronic neuroinflammation, leading to progressive loss of function and limited treatment options that only address symptoms.
Solution
Five Discovery is developing a new class of non‑hallucinogenic small‑molecule neuroplastogens that act on rapid‑acting serotonergic pathways to repair and stabilize these dysfunctional circuits. The molecules are designed to promote durable neural plasticity, reduce neuroinflammation, and rebalance serotonin–dopamine signaling, thereby addressing the root biological drivers of conditions such as Parkinson’s disease, Alzheimer’s disease, and traumatic brain injury. By focusing on circuit repair rather than symptomatic relief, the approach aims to deliver lasting therapeutic benefit across multiple neurodegenerative indications.
Target Audience
Primary customers are pharmaceutical companies and research organizations developing therapies for neurodegenerative disorders and brain injury, as well as clinical programs seeking disease‑modifying treatments.
Features
- Small‑molecule agents derived from 5‑MeO‑DMT mechanisms that retain neuroplastic effects without hallucinogenic activity
- Engineered to enhance durable neural plasticity and restore impaired brain circuitry
- Integrated anti‑inflammatory action to mitigate chronic neuroinflammation
- Dual modulation of serotonin and dopamine pathways for balanced neurotransmission
- Designed for oral administration with optimized pharmacokinetic and safety profiles